In this podcast interview live from ASCO GU24 in San Francisco, UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to medical oncologist Dr. Kim Chi from the University of British Columbia, Canada, about the CONTACT-2 trial. This randomised phase 3 trial aimed to evaluate the efficacy of cabozantinib + atezolizumab vs. second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).


Dr. Chi shares his interpretation of the study design and the main outcomes, including the safety profile. During the interview, Dr. Chi also explains why he does not believe it will become the new standard of care for patients with mCRPC, and details the more preferrable options  available for this patient population.

For more details on this trial, you can read the abstract ([ Ссылка ]) on the UROONCO Prostate Cancer educational platform.

свернуть